From available case reports, compounding pharmacy data, and practitioner experience, the following have been observed: BPC-157 Reported Side Effects Nausea and gastrointestinal discomfort (especially with oral administration) Dizziness or light-headedness Flushing or warmth at injection sites Headache Fatigue or somnolence in some users TB-500 Reported Side Effects Injection site reactions (redness, mild pain, swelling) Transient fatigue or lethargy following administration Headache Possible flu-like symptoms in a minority of users Critical Risk Note: Because neither peptide has undergone full clinical trial evaluation in humans, the complete adverse event profile is unknown
Presented for research literature review only Picchianti M et al
The peptide promotes angiogenesis the formation of new blood vessels through signaling pathways including VEGFR2
Some patients report a pale or yellowish tinge to the skin, and glossitis (a sore, red tongue) may develop
Supplementation that raises glutathione levels can also help older adults in good health with their cognition
The Australian Therapeutic Goods Administration added AOD-9604 to its Poisons Standard under performance and image-enhancing drugs (PIEDs), and possession without a legal prescription is restricted in Australia